Technology & Software Global On demand · 24-48h

Global Renal Denervation (RDN) Therapy Market Strategic Research Report

Name: Global Renal Denervation (RDN) Therapy Market Strategic Research Report
Brand: Market Research Reports, Inc.
Price: 3500 USD
Availability: PreOrder

Global Renal Denervation (RDN) Therapy Market Strategic Rese…

$3,500 USD

Strategic Research Report

Global Renal Denervation (RDN) Therapy Market

$2.15B2025

37.8%CAGR

2032Forecast

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Radio Frequency, Ultrasonic

By Application: Hospital, Clinic, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Medtronic (Covidien), ReCor, Johnson & Johnson, Boston Scientific, Shanghai Golden Leaf Med Tec Co., Ltd, Bio-Heart, SyMap Medical, Venus Medtech, Shanghai Microport Ep Medtech Co., Ltd., Cryofocus Medtech

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2025 · forecast to 2032

Length: 96 pages

Market size 2025

$2.15B

Billion USD

Forecast CAGR

37.8%

2025-2032

Forecast 2032

$20.3B

Projected

区域

Asia Pacific · Latin America · MEA · Europe · North America

概述

Scope of the Report

The global Renal Denervation (RDN) Therapy market size is predicted to grow from US$ 2,148 million in 2025 to US$ 19,490 million in 2032; it is expected to grow at a CAGR of 37.8% from 2026 to 2032.

Global key Renal Denervation (RDN) Therapy players cover Medtronic (Covidien), ReCor, Johnson & Johnson, Boston Scientific, Shanghai Golden Leaf Med Tec Co., Ltd, etc.

This report presents a comprehensive overview of the global Renal Denervation (RDN) Therapy market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Radio Frequency
Ultrasonic

Segment by Application

Hospital
Clinic
Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Renal Denervation (RDN) Therapy market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Hospital, Clinic, Other evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Renal Denervation (RDN) Therapy Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports

Market size CAGR 37.8%

Regional growth momentum

Market share by segment

Key metrics

Base value

$2.15B

2025

Forecast

$20.3B

2032

CAGR

37.8%

2025–2032

区域

global

Key companies

Medtronic (Covidien)ReCorJohnson & JohnsonBoston ScientificShanghai Golden Leaf Med Tec Co., LtdBio-HeartSyMap MedicalVenus Medtech

Segments covered in this report

By Type

Radio FrequencyUltrasonic

By Application

HospitalClinicOther

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 Radio Frequency
3.1.3 Ultrasonic
3.1.4 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Hospital
4.1.3 Clinic
4.1.4 Other
4.1.5 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 China
6.1.2 Japan
6.1.3 Korea
6.1.4 Southeast Asia
6.1.5 India
6.1.6 Australia
6.1.7 Rest of Asia Pacific
6.2 North America
6.2.1 United States
6.2.2 Canada
6.2.3 Mexico
6.2.4 Rest of North America
6.3 Europe
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Russia
6.3.6 Rest of Europe
6.4 Middle East & Africa
6.4.1 Egypt
6.4.2 South Africa
6.4.3 Israel
6.4.4 Turkey
6.4.5 GCC Countries
6.4.6 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Brazil
6.5.2 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 Medtronic (Covidien)
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 ReCor
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 Johnson & Johnson
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 Boston Scientific
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 Shanghai Golden Leaf Med Tec Co., Ltd
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 Bio-Heart
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 SyMap Medical
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 Venus Medtech
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 Shanghai Microport Ep Medtech Co.,Ltd.
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 Cryofocus Medtech
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Renal Denervation (RDN) Therapy market?

The global Renal Denervation (RDN) Therapy market is estimated at US$ 2.15 billion in 2025 (base year) and is projected to reach US$ 19.49 billion by 2032.

What is the forecast CAGR for the Renal Denervation (RDN) Therapy market?

The market is expected to grow at a CAGR of 37.8% from 2026 to 2032, expanding from US$ 2.15 billion in 2025 to US$ 19.49 billion in 2032, roughly 9.1 times its base-year value.

What is Renal Denervation (RDN) Therapy?

Global key Renal Denervation (RDN) Therapy players cover Medtronic (Covidien), ReCor, Johnson & Johnson, Boston Scientific, Shanghai Golden Leaf Med Tec Co., Ltd, etc.

What are the main segments of the Renal Denervation (RDN) Therapy market by type?

By type, the market is segmented into Radio Frequency and Ultrasonic.

Which applications drive demand in the Renal Denervation (RDN) Therapy market?

Key applications covered include Hospital, Clinic and Other.

Who are the key players in the Renal Denervation (RDN) Therapy market?

Key players profiled include Medtronic (Covidien), ReCor, Johnson & Johnson, Boston Scientific, Shanghai Golden Leaf Med Tec Co., Bio-Heart, SyMap Medical and Venus Medtech, among 10 companies covered in total.

Which regions and countries are covered for Renal Denervation (RDN) Therapy?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

Who should buy the Renal Denervation (RDN) Therapy market report?

The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Clinic and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Renal Denervation (RDN) Therapy market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.